Adaptimmune Therapeutics's market cap is currently ―. The company's EPS TTM is $-0.523; its P/E ratio is -2.18; Adaptimmune Therapeutics is scheduled to report earnings on May 6, 2024, and the estimated EPS forecast is $-0.15. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 231.00K	$ 7.32M	$ 5.13M	$ 47.60M	$ 11.03M
Gross Profit	$ 231.00K	$ 7.32M	$ 5.13M	$ 47.60M	$ 11.03M
EBIT	$ -48.57M	$ -44.91M	$ -20.71M	$ 1.66M	$ -28.26M
EBITDA	$ -46.09M	$ -42.98M	$ -19.22M	$ 3.62M	$ -26.46M
Net Income Common Stockholders	$ -47.92M	$ -45.49M	$ -21.39M	$ 1.04M	$ -29.25M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 146.94M	$ 161.73M	$ 204.71M	$ 165.55M	$ 204.60M
Total Assets	$ 282.62M	$ 296.64M	$ 342.98M	$ 288.08M	$ 328.92M
Total Debt	$ 25.23M	$ 25.60M	$ 26.34M	$ 22.83M	$ 23.08M
Net Debt	$ -121.70M	$ -136.13M	$ -178.37M	$ -142.72M	$ -181.53M
Total Liabilities	$ 243.10M	$ 208.51M	$ 216.33M	$ 204.21M	$ 247.04M
Stockholders Equity	$ 39.51M	$ 88.13M	$ 126.65M	$ 83.88M	$ 81.88M
Cash Flow	-
Free Cash Flow	$ -14.38M	$ -45.45M	$ -45.00M	$ -39.80M	$ -1.39M
Operating Cash Flow	$ -14.68M	$ -45.16M	$ -43.76M	$ -37.28M	$ 2.04M
Investing Cash Flow	$ 68.20M	$ 57.31M	$ 2.69M	$ 48.34M	$ 20.95M
Financing Cash Flow	$ 74.00K	$ 596.00K	$ 14.00K	$ 196.00K	$ 1.40M

Currency in USD

Adaptimmune Therapeutics Earnings and Revenue History

Income Statement >

Adaptimmune Therapeutics Debt to Assets

Balance Sheet >

Adaptimmune Therapeutics Cash Flow

Cash Flow >

Adaptimmune Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing